BioStock 27 august: CombiGene comments the international patent application

Aug 27, 2021

The gene therapy company CombiGene announced yesterday that it has submitted a PCT application to protect the vectors developed within the lipodystrophy project CGT2. This application opens up for future patent protection in approximately 150 countries. CombiGene’s CEO Jan Nilsson informs BioStock about the progress of the project and the long-term importance of potentially securing almost global patent protection.

To BioStock >>

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Medicon Village, SE-223-81 Lund

 

Linked In     Twitter      Facebook